## Clinical Context IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Progressive renal dysfunction in a patient on tacrolimus requires systematic evaluation to distinguish between: 1. **Inadequate immunosuppression** (disease progression) 2. **Tacrolimus-induced nephrotoxicity** (drug-related) 3. **Uncontrolled hypertension** (secondary injury) 4. **Non-adherence** (subtherapeutic levels) ## Diagnostic and Management Algorithm ```mermaid flowchart TD A[IgAN on tacrolimus with rising Cr]:::outcome --> B[Check tacrolimus trough level]:::action B --> C{Trough adequate?}:::decision C -->|No| D[Optimize tacrolimus dosing]:::action C -->|Yes| E{BP controlled?}:::decision E -->|No| F[Intensify antihypertensive therapy]:::action E -->|Yes| G{Proteinuria > 3 g/day?}:::decision F --> H[Reassess in 4-6 weeks]:::action G -->|Yes| I[Add mycophenolate mofetil]:::action G -->|No| H I --> H H --> J{Improvement?}:::decision J -->|No| K[Consider repeat renal biopsy]:::action J -->|Yes| L[Continue optimized regimen]:::outcome ``` ## Stepwise Approach to Progressive Renal Dysfunction ### Step 1: Verify Tacrolimus Levels **Key Point:** Tacrolimus has a narrow therapeutic window (8–12 ng/mL for renal disease). The current trough of 8 ng/mL is at the lower end; however, **higher levels do not automatically improve outcomes and increase nephrotoxicity risk**. - Confirm adherence to dosing - Check for drug interactions (NSAIDs, ACE inhibitors, other calcineurin inhibitors) - Assess for signs of tacrolimus toxicity (tremor, hyperglycaemia, gingival hyperplasia) ### Step 2: Optimize Blood Pressure Control **High-Yield:** Hypertension is a major modifiable risk factor in progressive renal disease. Current BP 165/105 mmHg is above target (goal < 130/80 mmHg in CKD). - Add or uptitrate antihypertensive agents (ACE-I or ARB as first-line) - Amlodipine is appropriate for additional BP control - Aggressive BP management can slow GFR decline by 20–30% ### Step 3: Assess Proteinuria Control **Clinical Pearl:** Persistent proteinuria > 3 g/day despite monotherapy indicates inadequate immunosuppression. Adding a second agent (mycophenolate mofetil) is evidence-based in IgAN. **Mnemonic for IgAN immunosuppression:** **TACRO-MMF** = Tacrolimus + Mycophenolate Mofetil is a validated combination for resistant IgAN. ### Step 4: Repeat Renal Biopsy (Only if No Improvement) Repeat biopsy is indicated only after 4–6 weeks of optimized therapy if: - Creatinine continues to rise - Proteinuria worsens - Need to exclude alternative diagnoses (e.g., secondary FSGS, drug-induced injury) ## Why This Approach Is Superior | Consideration | Rationale | |---|---| | **Check trough level first** | Ensures current dosing is adequate; guides dose adjustment without guessing | | **Optimize BP control** | Hypertension is a major, reversible driver of CKD progression | | **Add MMF for proteinuria** | Evidence-based dual therapy for resistant IgAN; improves renal outcomes | | **Defer repeat biopsy** | Unnecessary at this stage; indicated only if clinical response is inadequate | ## Why Other Options Are Suboptimal **Option 1 (Increase tacrolimus to 12–15 ng/mL):** - Higher tacrolimus levels increase nephrotoxicity risk without proven benefit in IgAN - Does not address hypertension, which is a major contributor to declining GFR - Ignores the need for dual immunosuppression in resistant proteinuria **Option 2 (Immediate repeat renal biopsy):** - Premature; clinical and biochemical optimization should precede biopsy - Biopsy carries risk (bleeding, infection) and is not indicated for diagnosis of tacrolimus toxicity (clinical diagnosis) - Repeat biopsy is appropriate only if therapy fails after 4–6 weeks **Option 4 (Switch to cyclophosphamide):** - Cyclophosphamide is reserved for severe, rapidly progressive IgAN or ANCA-associated vasculitis - This patient has stable, progressive disease—not rapidly progressive GN - Cyclophosphamide has greater toxicity (infertility, malignancy, infection) and is not first-line for IgAN [cite:Harrison 21e Ch 279; KD Tripathi 8e Ch 12]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.